Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Tongue carcinoma infrequently harbor common actionable genetic alterations

Authors: Daniel SW Tan, Weining Wang, Hui Sun Leong, Pui Hoon Sew, Dawn P Lau, Fui Teen Chong, Sai Sakktee Krisna, Tony KH Lim, N Gopalakrishna Iyer

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Oral tongue squamous cell carcinomas (TSCC) are a unique subset of head and neck cancers with a distinct demographic profile, where up to half of the cases are never smokers. A small proportion of patients with OSCC are known to respond to EGFR TKI. We used a high-sensitivity mass spectrometry-based mutation profiling platform to determine the EGFR mutation status, as well as other actionable alterations in a series of Asian TSCC.

Methods

66 TSCC patients treated between 1998-2009 with complete clinico-pathologic data were included in this study. Somatic mutation profiling was performed using Sequenom LungCarta v1.0, and correlated with clinical parameters.

Results

Mutations were identified in 20/66(30.3%) of samples and involved TP53, STK11, MET, PIK3CA, BRAF and NRF2. No activating EGFR mutations or KRAS mutations were discovered in our series, where just over a third were never smokers. The most common mutations were in p53 (10.6%; n = 7) and MET (10.6%, n = 11) followed by STK11 (9.1%, n = 6) and PIK3CA (4.5%, n = 3). BRAF and NRF2 mutations, which are novel in TSCC, were demonstrated in one sample each. There was no significant correlation between overall mutation status and smoking history (p = 0.967) or age (p = 0.360). Positive MET alteration was associated with poorer loco-regional recurrence free survival (LRFS) of 11 months [vs 90 months in MET-negative group (p = 0.008)]. None of the other mutations were significantly correlated with LRFS or overall survival. Four of these tumors were propagated as immortalized cell lines and demonstrated the same mutations as the original tumor.

Conclusions

Using the Sequenom multiplexed LungCarta panel, we identified mutations in 6 genes, TP53, STK11, MET, PIK3CA, BRAF and NRF2, with the notable absence of EGFR and HER2 mutations in our series of Asian OSCC. Primary cell line models recapitulated the mutation profiles of the original primary tumours and provide an invaluable resource for experimental cancer therapeutics.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Krishna Rao SV, Mejia G, Roberts-Thomson K, Logan R: Epidemiology of oral cancer in Asia in the past decade–an update (2000–2012). Asian Pac J Cancer Prev. 2013, 14 (10): 5567-5577. 10.7314/APJCP.2013.14.10.5567.CrossRefPubMed
4.
Yip CS, Charn TC, Wee JT, Tan TW, Goh C, Tan HK, Fong KW: Outcomes of oral tongue cancer: does age matter?. Ann Acad Med Singapore. 2010, 39: 897-PubMed
5.
Chaturvedi AK, Engels EA, Anderson WF, Gillison ML: Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008, 26: 612-619. 10.1200/JCO.2007.14.1713.CrossRefPubMed
6.
Krishnamurthy A, Ramshankar V: Early stage oral tongue cancer among non-tobacco users - An increasing trend observed in a South Indian patient population presenting at a single centre. Asian Pac J Cancer Prev. 2013, 14: 5061-5065. 10.7314/APJCP.2013.14.9.5061.CrossRefPubMed
7.
8.
Bodner L, Manor E, Friger MD, van der Waal I: Oral squamous cell carcinoma in patients twenty years of age or younger - Review and analysis of 186 reported cases. Oral Oncol. 2014, 50 (2): 84-89. 10.1016/j.oraloncology.2013.11.001.CrossRefPubMed
9.
Patel SC, Carpenter WR, Tyree S, Couch ME, Weissler M, Hackman T, Hayes DN, Shores C, Chera BS: Increasing incidence of oral tongue squamous cell carcinoma in young white women, age 18 to 44 years. J Clin Oncol. 2011, 29: 1488-1494. 10.1200/JCO.2010.31.7883.CrossRefPubMed
10.
Byers RM, Weber RS, Andrews T, McGill D, Kare R, Wolf P: Frequency and therapeutic implications of “skip metastases” in the neck from squamous carcinoma of the oral tongue. Head Neck. 1997, 19 (1): 14-19. 10.1002/(SICI)1097-0347(199701)19:1<14::AID-HED3>3.0.CO;2-Y.CrossRefPubMed
11.
Zelefsky MJ, Harrison LB, Fass DE, Armstrong J, Spiro RH, Shah JP, Strong EW: Postoperative radiotherapy for oral cavity cancers: impact of anatomic subsite on treatment outcome. Head Neck. 1990, 12 (6): 470-475. 10.1002/hed.2880120604.CrossRefPubMed
12.
India Project Team of the International Cancer Genome Consortium: Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups. Nat Commun. 2013, 4: 2873-
13.
14.
Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, da Chu T, Zaatar A, Osorio Sanchez JA, Vu VV, Au JS, Inoue A, Lee SM, Gebski V, Yang JC: Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013, 105 (9): 595-605. 10.1093/jnci/djt072.CrossRefPubMed
15.
Cohen EE, Halpern AB, Kasza K, Kocherginsky M, Williams R, Vokes EE: Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2009, 45: e155-e160. 10.1016/j.oraloncology.2009.05.637.CrossRefPubMed
16.
Bontognali S, Pless M, Brutsche MH, Fischer C, Rochlitz C, Buess M: Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib. Onkologie. 2013, 36 (4): 161-166. 10.1159/000349941.CrossRefPubMed
17.
Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Hargreaves L, Armour A, Speake G, Swaisland A, Vokes EE: Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009, 27 (11): 1864-1871. 10.1200/JCO.2008.17.0530.CrossRefPubMed
18.
Kirby AM, A’Hern RP, D’Ambrosio C, Tanay M, Syrigos KN, Rogers SJ, Box C, Eccles SA, Nutting CM, Harrington KJ: Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer. 2006, 94 (5): 631-636.PubMedPubMedCentral
19.
Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE: Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005, 11: 8418-8424. 10.1158/1078-0432.CCR-05-1247.CrossRefPubMed
20.
Wheeler RH, Jones D, Sharma P, Davis RK, Spilker H, Boucher K, Leachman S, Grossman D, Salzman K, Akerley W: Clinical and molecular Phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca). J Clin Oncol. 2005, 23: 5531-Meeting Abstracts
21.
Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003, 21 (10): 1980-1987. 10.1200/JCO.2003.10.051.CrossRefPubMed
22.
Thomas F, Rochaix P, Benlyazid A, Sarini J, Rives M, Lefebvre JL, Allal BC, Courbon F, Chatelut E, Delord JP: Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clin Cancer Res. 2007, 13 (23): 7086-7092. 10.1158/1078-0432.CCR-07-1370.CrossRefPubMed
23.
Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004, 22 (1): 77-85.CrossRefPubMed
24.
25.
26.
Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Treviño L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzler KW, et al: Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011, 333: 1154-1157. 10.1126/science.1206923.CrossRefPubMedPubMedCentral
27.
Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, et al: The mutational landscape of head and neck squamous cell carcinoma. Science. 2011, 333: 1157-1160. 10.1126/science.1208130.CrossRefPubMedPubMedCentral
28.
Hsieh CH, Chang JW, Hsieh JJ, Hsu T, Huang SF, Liao CT, Wang HM: Epidermal growth factor receptor mutations in patients with oral cavity cancer in a betel nut chewing-prevalent area. Head Neck. 2011, 33 (12): 1758-1764. 10.1002/hed.21665.CrossRefPubMed
29.
Huang SF, Chuang WY, Chen IH, Liao CT, Wang HM, Hsieh LL: EGFR protein overexpression and mutation in areca quid-associated oral cavity squamous cell carcinoma in Taiwan. Head Neck. 2009, 31 (8): 1068-1077. 10.1002/hed.21067.CrossRefPubMed
30.
Sheikh Ali MA, Gunduz M, Nagatsuka H, Gunduz E, Cengiz B, Fukushima K, Beder LB, Demircan K, Fujii M, Yamanaka N, Shimizu K, Grenman R, Nagai N: Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci. 2008, 99: 1589-1594. 10.1111/j.1349-7006.2008.00861.x.CrossRefPubMed
31.
Lemos-González Y, Páez de la Cadena M, Rodríguez-Berrocal FJ, Rodríguez-Piñeiro AM, Pallas E, Valverde D: Absence of activating mutations in the EGFR kinase domain in Spanish head and neck cancer patients. Tumour Biol. 2007, 28 (5): 273-279. 10.1159/000110425.CrossRefPubMed
32.
Na II, Kang HJ, Cho SY, Koh JS, Lee JK, Lee BC, Lee GH, Lee YS, Yoo HJ, Ryoo BY, Yang SH, Shim YS: EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. Eur J Cancer. 2007, 43: 520-526. 10.1016/j.ejca.2006.09.025.CrossRefPubMed
33.
Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, Jarrett C, Carter J, Murphy BA, Netterville J, Burkey BB, Sinard R, Cmelak A, Levy S, Yarbrough WG, Slebos RJ, Hirsch FR: Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol. 2006, 24 (25): 4170-4176. 10.1200/JCO.2006.07.2587.CrossRefPubMed
34.
Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, Hilbe W, Schwentner I, Sprinzl GM, Utermann G, Zwierzina H: Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer. 2006, 42 (1): 109-111. 10.1016/j.ejca.2005.08.034.CrossRefPubMed
35.
Lee JW, Soung YH, Kim SY, Nam HK, Park WS, Nam SW, Kim MS, Sun DI, Lee YS, Jang JJ, Lee JY, Yoo NJ, Lee SH: Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005, 11 (8): 2879-2882. 10.1158/1078-0432.CCR-04-2029.CrossRefPubMed
36.
Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DW: Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005, 11: 8105-8108. 10.1158/1078-0432.CCR-05-0926.CrossRefPubMed
37.
Willmore-Payne C, Holden JA, Layfield LJ: Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Mod Pathol. 2006, 19 (5): 634-640. 10.1038/modpathol.3800552.CrossRefPubMed
38.
Nguyen TK, Iyer NG: Genetic alterations in head and neck squamous cell carcinoma: The next-gen sequencing era. World J Med Genet. 2013, 3: 22-33. 10.5496/wjmg.v3.i4.22.CrossRef
39.
Zanaruddin SN, Yee PS, Hor SY, Kong YH, Ghani WM, Mustafa WM, Zain RB, Prime SS, Rahman ZA, Cheong SC: Common oncogenic mutations are infrequent in oral squamous cell carcinoma of Asian origin. PLoS One. 2013, 8 (11): e80229-10.1371/journal.pone.0080229.CrossRefPubMedPubMedCentral
40.
Tan DS, Camilleri-Broët S, Tan EH, Alifano M, Lim WT, Bobbio A, Zhang S, Ng QS, Ang MK, Iyer NG, Takano A, Lim KH, Régnard JF, Tan P, Broët P: Intertumour heterogeneity of non-small cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics. Int J Cancer. 2014, 135 (5): 1092-1100. 10.1002/ijc.28750.CrossRefPubMed
41.
Fumagalli D, Gavin PG, Taniyama Y, Kim SI, Choi HJ, Paik S, Pogue-Geile KL: A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer. 2010, 10: 101-10.1186/1471-2407-10-101. doi:10.1186/1471-2407-10-101CrossRefPubMedPubMedCentral
42.
Leong HS, Chong FT, Sew PH, Lau DP, Wong BH, Teh BT, Tan DS, Iyer NG: Targeting Cancer Stem Cell Plasticity Through Modulation of Epidermal Growth Factor and Insulin-Like Growth Factor Receptor Signaling in Head and Neck Squamous Cell Cancer. Stem Cells Transl Med. 2014, 3 (9): 1055-1065. 10.5966/sctm.2013-0214. doi:10.5966/sctm.2013-2014. Epub 2014 Jul 14CrossRefPubMedPubMedCentral
43.
Riethdorf S, Friedrich RE, Ostwald C, Barten M, Gogacz P, Gundlach KK, Schlechte H, Becker J, Bregenzer T, Riethdorf L, Löning T: p53 gene mutations and HPV infection in primary head and neck squamous cell carcinomas do not correlate with overall survival: a long-term follow-up study. J Oral Pathol Med. 1997, 26 (7): 315-321. 10.1111/j.1600-0714.1997.tb00222.x.CrossRefPubMed
44.
Hunt JL, Barnes L, Lewis JS, Mahfouz ME, Slootweg PJ, Thompson LD, Cardesa A, Devaney KO, Gnepp DR, Westra WH, Rodrigo JP, Woolgar JA, Rinaldo A, Triantafyllou A, Takes RP, Ferlito A: Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications. Eur Arch Otorhinolaryngol. 2014, 271 (2): 211-223. 10.1007/s00405-013-2400-9.CrossRefPubMed
45.
Linehan WM, Ricketts CJ: The metabolic basis of kidney cancer. Semin Cancer Biol. 2013, 23: 46-55. 10.1016/j.semcancer.2012.06.002.CrossRefPubMed
46.
Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R: The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009, 69: 3021-3031.CrossRefPubMedPubMedCentral
47.
Peters S, Adjei AA: MET: A promising anticancer therapeutic target. Nat Rev Clin Oncol. 2012, 9: 314-326. 10.1038/nrclinonc.2012.71.CrossRefPubMed
48.
Knudsen BS, Vande Woude G: Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev. 2008, 18: 87-96. 10.1016/j.gde.2008.02.001.CrossRefPubMed
49.
Shieh JM, Tang YA, Yang TH, Chen CY, Hsu HS, Tan YH, Salgia R, Wang YC: Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis. Int J Med Sci. 2013, 10: 988-994. 10.7150/ijms.5944.CrossRefPubMedPubMedCentral
50.
Qiu W, Schönleben F, Thaker HM, Goggins M, Su GH: A novel mutation of STK11/LKB1 gene leads to the loss of cell growth inhibition in head and neck squamous cell carcinoma. Oncogene. 2006, 25: 2937-2942. 10.1038/sj.onc.1209325.CrossRefPubMedPubMedCentral
51.
Weber A, Langhanki L, Sommerer F, Markwarth A, Wittekind C, Tannapfel A: Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene. 2003, 22: 4757-4759. 10.1038/sj.onc.1206705.CrossRefPubMed
52.
Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O’Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF: Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012, 19;379 (9829): 1893-2901.CrossRef
53.
Bahadoran P, Allegra M, Le Duff F, Long-Mira E, Hofman P, Giacchero D, Passeron T, Lacour JP, Ballotti R: Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma. J Clin Oncol. 2013, 31: e324-e326. 10.1200/JCO.2012.46.1061.CrossRefPubMed
54.
Stacy DR, Ely K, Massion PP, Yarbrough WG, Hallahan DE, Sekhar KR, Freeman ML: Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck. 2006, 28: 813-818. 10.1002/hed.20430.CrossRefPubMed
55.
Shibata T, Saito S, Kokubu A, Suzuki T, Yamamoto M, Hirohashi S: Global downstream pathway analysis reveals a dependence of oncogenic NF-E2 - Related factor 2 mutation on the mTOR growth signaling pathway. Cancer Res. 2010, 70: 9095-9105. 10.1158/0008-5472.CAN-10-0384.CrossRefPubMed
56.
Kim YR, Oh JE, Kim MS, Kang MR, Park SW, Han JY, Eom HS, Yoo NJ, Lee SH: Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol. 2010, 220: 446-451. 10.1002/path.2653.CrossRefPubMed
Metadata
Title
Tongue carcinoma infrequently harbor common actionable genetic alterations
Authors
Daniel SW Tan
Weining Wang
Hui Sun Leong
Pui Hoon Sew
Dawn P Lau
Fui Teen Chong
Sai Sakktee Krisna
Tony KH Lim
N Gopalakrishna Iyer
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-679

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Case report

FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities

Case report

Solitary breast metastasis from myxoid liposarcoma

Research article

Embelin inhibits TNF-α converting enzyme and cancer cell metastasis: molecular dynamics and experimental evidence

Research article

Pattern of use of radiotherapy for lung cancer: a descriptive study

Research article

Non-small cell lung cancer with EML4-ALKtranslocation in Chinese male never-smokers is characterized with early-onset

Research article

The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits